Monitoring NLRP3 Inflammasome Activation and Exhaustion in Clinical Samples: A Refined Flow Cytometry Protocol for ASC Speck Formation Measurement Directly in Whole Blood after Ex Vivo Stimulation

Cells. 2022 Oct 20;11(20):3306. doi: 10.3390/cells11203306.

Abstract

Alteration of NLRP3 inflammasome pathway including hyper-activation or exhaustion has been implicated in the pathophysiology of many diseases. Following cell stimulation, aggregation of the ASC protein into a multiprotein complex, the ASC speck, has been proposed as a specific read-out for monitoring NLRP3 inflammasome activation by flow cytometry in clinical samples. So far, only a few papers have described a technique to detect ASC speck formation directly in whole blood without any cell purification, and none included an ex vivo stimulation. The objective of this study was thus to develop a simple and shortened flow cytometry protocol to detect ASC speck formation directly in whole blood including an ex vivo stimulation step. We showed that after red blood cells lysis and removal of the LPS stimulation step, ASC speck formation can be detected in both monocytes and neutrophils from healthy donors directly in nigericin-stimulated whole blood samples. Using samples from four septic shock patients, we showed that this technique allows for the detection of NLRP3 inflammasome exhaustion in clinical samples. This novel shortened and simple whole blood protocol should facilitate day-to-day monitoring of NLRP3 inflammasome activation and exhaustion in both monocytes and neutrophils in clinical studies.

Trial registration: ClinicalTrials.gov NCT04067674.

Keywords: ASC speck; NLRP3 inflammasome; flow cytometry; protocol; whole blood.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CARD Signaling Adaptor Proteins / metabolism
  • Flow Cytometry / methods
  • Humans
  • Inflammasomes* / metabolism
  • Lipopolysaccharides
  • NLR Family, Pyrin Domain-Containing 3 Protein* / metabolism
  • Nigericin

Substances

  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • CARD Signaling Adaptor Proteins
  • Lipopolysaccharides
  • Nigericin

Associated data

  • ClinicalTrials.gov/NCT04067674

Grants and funding

This work was supported by the Hospices Civils de Lyon, Fondation HCL, Claude Bernard Lyon 1 University and Région Auvergne Rhône-Alpes.